TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31585522

Group type: EXPERIMENTAL
Intervention: Low-level laser therapy (LLLT)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Placebo LLLT
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Active LLLT
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Information about treatment
Number of subjects: 41
Study: 30359072

Group type: EXPERIMENTAL
Intervention: Sleep restriction over 2 days
Number of subjects: 142

Group type: COMPARATOR
Intervention: Maintained sleep over 2 days
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: Sleep restriction
Number of subjects: 142
Study: 29614401

Group type: EXPERIMENTAL
Intervention: DIGIT training program
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: PLUS training program
Number of subjects: 49

Group type: COMPARATOR
Intervention: Control group (20 preschoolers with no mathematical difficulties)
Number of subjects: 49
Study: 26982446

Group type: EXPERIMENTAL
Intervention: Text messaging intervention for medication adherence or symptom severity
Number of subjects: 462

Group type: EXPERIMENTAL
Intervention: Text messaging intervention
Number of subjects: 462
Study: 24737712

Group type: EXPERIMENTAL
Intervention: Anacetrapib
Number of subjects: 803
Study: 22796985

Group type: EXPERIMENTAL
Intervention: Nicotine transdermal patches
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo transdermal patches
Number of subjects: 15
Study: 19703761

Group type: EXPERIMENTAL
Intervention: GLA+prandial insulin lispro (LIS)
Number of subjects: 395

Group type: COMPARATOR
Intervention: GLA+prandial regular human insulin (RHI)
Number of subjects: 395

Group type: EXPERIMENTAL
Intervention: Both treatments (LIS and RHI)
Number of subjects: 395
Study: 17351283

Group type: EXPERIMENTAL
Intervention: Motivational interviewing
Number of subjects: 66

Group type: COMPARATOR
Intervention: Support visits (Control)
Number of subjects: 66
Study: 16327946

Group type: EXPERIMENTAL
Intervention: Oral Pycnogenol
Number of subjects: 18

Group type: COMPARATOR
Intervention: Combination treatment (oral and local)
Number of subjects: 18
Study: 12017143

Group type: EXPERIMENTAL
Intervention: On-line domestic violence education program
Number of subjects: 65

Group type: COMPARATOR
Intervention: Control group (did not take the program)
Number of subjects: 65
Study: 10589610

Group type: EXPERIMENTAL
Intervention: Sodium nitroprusside (SNP)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control
Number of subjects: 30
Study: 7608367

Group type: EXPERIMENTAL
Intervention: Glass ionomer cement
Number of subjects: 47

Group type: COMPARATOR
Intervention: Resin fissure sealant
Number of subjects: 47
Study: 2239719

Group type: EXPERIMENTAL
Intervention: Triglyceride fish oil (6 g/day)
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Ethyl ester fish oil (7 g/day)
Number of subjects: 89

Group type: COMPARATOR
Intervention: Olive oil (12 g/day)
Number of subjects: 89
Study: 35925

Group type: EXPERIMENTAL
Intervention: Mianserin
Number of subjects: 0
Study: 31842993

Group type: EXPERIMENTAL
Intervention: 3-day treatment with 40 mg prednisone daily followed by 2 days of placebo (experimental arm, n = 235)
Number of subjects: 470

Group type: COMPARATOR
Intervention: 5-day treatment with 40 mg prednisone daily (conventional arm, n = 235)
Number of subjects: 470
Study: 28969350

Group type: EXPERIMENTAL
Intervention: Hip abductor strength in surgical limb pre-TKA
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: Hip abductor strength in surgical limb 1 month post-TKA
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: Hip abductor strength in surgical limb 3 months post-TKA
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: Change in hip abductor strength from pre-TKA to 1 month post-TKA
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: Change in hip abductor strength from 1 month to 3 months post-TKA
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: Contribution of hip abductor strength to performance-based outcomes pre-TKA
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: Contribution of hip abductor strength to performance-based outcomes post-TKA
Number of subjects: 162
Study: 26414337

Group type: EXPERIMENTAL
Intervention: Varenicline (2 mg daily, titrated from 0.5 mg during first week)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Varenicline
Number of subjects: 160

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 160
Study: 22392603

Group type: EXPERIMENTAL
Intervention: Daily oral iron therapy
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: Twice weekly oral iron therapy
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: Once weekly oral iron therapy
Number of subjects: 148
Study: 21397895

Group type: EXPERIMENTAL
Intervention: Exposure only
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Exposure with safety behavior availability
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Exposure with safety behavior utilization
Number of subjects: 58
Study: 19770129

Group type: EXPERIMENTAL
Intervention: Cisplatin (CDDP) 80 mg/m² on day 1 and irinotecan 60 mg/m² on days 1 and 8 followed by accelerated hyperfractionated thoracic radiotherapy (60 Gy/40 fractions in 4 weeks) with daily carboplatin (CBDCA) administration.
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Cisplatin (CDDP) and irinotecan chemotherapy followed by radiotherapy with daily carboplatin.
Number of subjects: 26
Study: 17288330

Group type: EXPERIMENTAL
Intervention: Light-activated resin composite with incremental technique
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Light-activated resin composite with bulk technique
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Chemical-activated resin composite with incremental technique
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Chemical-activated resin composite with bulk technique
Number of subjects: 40
Study: 14724304

Group type: EXPERIMENTAL
Intervention: 800 mg of albendazole per day and 6 mg of dexamethasone per day for 10 days
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study: 12572707

Group type: EXPERIMENTAL
Intervention: Doxazosin
Number of subjects: 80

Group type: COMPARATOR
Intervention: Hydrochlorothiazide (HCTZ)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Both Doxazosin and HCTZ
Number of subjects: 80
Study: 9498726

Group type: EXPERIMENTAL
Intervention: Sertindole 12 mg daily with alprazolam 1 mg
Number of subjects: 14
Study: 7620470

Group type: EXPERIMENTAL
Intervention: Behavioral family systems therapy (BFST)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Ego-oriented individual therapy (EOIT)
Number of subjects: 22
Study: 2131867

Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.5% with epinephrine 1:200,000
Number of subjects: 15

Group type: COMPARATOR
Intervention: Plain bupivacaine 0.5%
Number of subjects: 15
Study: 31846795

Group type: EXPERIMENTAL
Intervention: Eczema (past/current)
Number of subjects: 12049

Group type: EXPERIMENTAL
Intervention: Scoring Atopic Dermatitis
Number of subjects: 12049

Group type: EXPERIMENTAL
Intervention: Antibiotics in the first week of life
Number of subjects: 12049

Group type: EXPERIMENTAL
Intervention: Current rhinitis
Number of subjects: 12049

Group type: EXPERIMENTAL
Intervention: Eczema severity
Number of subjects: 12049

Group type: EXPERIMENTAL
Intervention: Age of introduction of egg into the diet
Number of subjects: 12049
Study: 31666778

Group type: EXPERIMENTAL
Intervention: Breast self-examination
Number of subjects: 810

Group type: EXPERIMENTAL
Intervention: Perceived severity of breast cancer
Number of subjects: 810

Group type: EXPERIMENTAL
Intervention: Self-efficacy
Number of subjects: 810

Group type: EXPERIMENTAL
Intervention: Districts
Number of subjects: 810

Group type: EXPERIMENTAL
Intervention: Place of residence
Number of subjects: 810

Group type: EXPERIMENTAL
Intervention: Health Belief Model (HBM)
Number of subjects: 810
Study: 30040523

Group type: COMPARATOR
Intervention: Placebo with doxorubicin and cyclophosphamide (AC) followed by weekly paclitaxel (arm A)
Number of subjects: 4994

Group type: EXPERIMENTAL
Intervention: Bevacizumab only during AC and paclitaxel (arm B)
Number of subjects: 4994

Group type: EXPERIMENTAL
Intervention: Bevacizumab during AC and paclitaxel followed by bevacizumab monotherapy for 10 cycles (arm C)
Number of subjects: 4994
Study: 27763932

Group type: EXPERIMENTAL
Intervention: Reiki
Number of subjects: 45

Group type: COMPARATOR
Intervention: Sham Reiki
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control
Number of subjects: 45
Study: 24866910

Group type: EXPERIMENTAL
Intervention: Breakfast consumption for one week
Number of subjects: 37

Group type: COMPARATOR
Intervention: No breakfast consumption for one week
Number of subjects: 37
Study: 21901486

Group type: EXPERIMENTAL
Intervention: Mixed breastfeeding (MBF)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Exclusive breastfeeding
Number of subjects: 0
Study: 19923501

Group type: EXPERIMENTAL
Intervention: 1500 mL of 6% HES 130/0.42 in a balanced electrolyte solution (n = 25)
Number of subjects: 50

Group type: COMPARATOR
Intervention: 500 mL of 5% human albumin plus 1000 mL 0.9% saline solution (n = 25)
Number of subjects: 50
Study: 17574511

Group type: EXPERIMENTAL
Intervention: mini-CPB
Number of subjects: 30

Group type: COMPARATOR
Intervention: conventional CPB
Number of subjects: 30
Study: 15480509

Group type: EXPERIMENTAL
Intervention: [(18)F] fluoromisonidazole (FMISO) PET
Number of subjects: 16

Group type: COMPARATOR
Intervention: [(18)F]-2-fluoro-2'-deoxyglucose (FDG) PET
Number of subjects: 16
Study: 11592538

Group type: EXPERIMENTAL
Intervention: Team midwife care
Number of subjects: 1000

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 1000
Study: 9560031

Group type: EXPERIMENTAL
Intervention: Hyperimmune bovine colostrum (n=42)
Number of subjects: 135

Group type: COMPARATOR
Intervention: Ordinary colostrum (n=42)
Number of subjects: 135

Group type: COMPARATOR
Intervention: Milk (n=41)
Number of subjects: 135
Study: 7635023

Group type: EXPERIMENTAL
Intervention: Gabapentin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Lamotrigine
Number of subjects: 0
Study: 2974791

Group type: EXPERIMENTAL
Intervention: DianeR (cyproterone acetate 2 mg and ethinylestradiol 50 micrograms per pill - D-50)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Diane 35 (cyproterone acetate 2 mg and ethinylestradiol 35 micrograms per pill - D-35)
Number of subjects: 30
Study: 29305893

Group type: EXPERIMENTAL
Intervention: Franseen needle
Number of subjects: 50

Group type: COMPARATOR
Intervention: Fork-tip needle
Number of subjects: 50
Study: 26239663

Group type: EXPERIMENTAL
Intervention: Volume-targeted ventilation (VTV)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Pressure-limited ventilation (PLV)
Number of subjects: 40
Study: 24656555

Group type: EXPERIMENTAL
Intervention: Self-administration of sc DMPA 104 mg
Number of subjects: 137

Group type: COMPARATOR
Intervention: Clinician administration of sc DMPA 104 mg
Number of subjects: 137
Study: 24429865

Group type: EXPERIMENTAL
Intervention: Candibiotic ear drops
Number of subjects: 0

Group type: COMPARATOR
Intervention: Otipax ear drops
Number of subjects: 0

Group type: COMPARATOR
Intervention: Anauran ear drops
Number of subjects: 0
Study: 20236172

Group type: EXPERIMENTAL
Intervention: Pregabalin 150-600 mg/day
Number of subjects: 254

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 254
Study: 17845740

Group type: EXPERIMENTAL
Intervention: Cluster A (elevated paranoid and schizotypal features)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Cluster B (elevated narcissistic and histrionic features)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Cluster C (elevated avoidant and obsessive-compulsive features)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Two dimensions underlying comorbid features: extraversion versus introversion and antagonism versus constraint
Number of subjects: 90
Study: 15864235

Group type: EXPERIMENTAL
Intervention: ezetimibe/simvastatin (10/10, 10/20, 10/40, or 10/80 mg)
Number of subjects: 1902

Group type: EXPERIMENTAL
Intervention: ezetimibe/simvastatin (10/40 and 10/80 mg)
Number of subjects: 1902

Group type: COMPARATOR
Intervention: atorvastatin (10, 20, 40, or 80 mg)
Number of subjects: 1902

Group type: EXPERIMENTAL
Intervention: ezetimibe/simvastatin
Number of subjects: 1902

Group type: COMPARATOR
Intervention: ezetimibe/simvastatin and atorvastatin
Number of subjects: 1902
Study: 12818960

Group type: EXPERIMENTAL
Intervention: Ibuprofen treatment
Number of subjects: 517
Study: 11029973

Group type: EXPERIMENTAL
Intervention: High-fat diet
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Exercise
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Exercise in restrained eaters
Number of subjects: 25

Group type: COMPARATOR
Intervention: Rest conditions
Number of subjects: 25
Study: 8852908

Group type: EXPERIMENTAL
Intervention: Aerosolized human IgG (Sandoglobulin) at a dose of 0.1 g/kg in a 5% solution, delivered in 2 parts on the day of hospital admission.
Number of subjects: 68

Group type: COMPARATOR
Intervention: Placebo, identical amount as the treatment group, delivered in 2 parts on the day of hospital admission.
Number of subjects: 68
Study: 8475011

Group type: EXPERIMENTAL
Intervention: Multicomponent intervention including physician involvement and community education effort
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not applicable (comparison community)
Number of subjects: 0
Study: 2880743

Group type: EXPERIMENTAL
Intervention: Lysine acetylsalicylate (LAS) infusion (66 mg/min for 120 min)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Somatostatin (SRIF) infusion (150 micrograms bolus followed by 100 micrograms/h for 120 min)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Arginine (25 g i.v. in 30 min)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Lysine acetylsalicylate (LAS) infusion
Number of subjects: 10
Study: 30089729

Group type: EXPERIMENTAL
Intervention: Endurance exercise (EE) - 1 hour of bicycling at 70% of VO2peak
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Resistance exercise (RE) - 1 hour of high-volume RE
Number of subjects: 10
Study: 26790922

Group type: EXPERIMENTAL
Intervention: 1 cm excision margin
Number of subjects: 900

Group type: COMPARATOR
Intervention: 3 cm excision margin
Number of subjects: 900
Study: 26384407

Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate (NaHCO3) ingestion (0.4 g/kg body weight)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate (NaHCO3) ingestion
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo (sodium chloride)
Number of subjects: 9
Study: 24267044

Group type: EXPERIMENTAL
Intervention: High-fructose corn syrup (HFCS)
Number of subjects: 138

Group type: COMPARATOR
Intervention: Sucrose
Number of subjects: 138
Study: 21616485

Group type: EXPERIMENTAL
Intervention: PGS
Number of subjects: 131

Group type: COMPARATOR
Intervention: Control
Number of subjects: 131
Study: 19090341

Group type: EXPERIMENTAL
Intervention: CLIN/RA gel (clindamycin phosphate 1.2%-tretinoin 0.025%)
Number of subjects: 655
Study: 16551762

Group type: EXPERIMENTAL
Intervention: Occupational health intervention programme
Number of subjects: 260

Group type: COMPARATOR
Intervention: Care as usual (Control)
Number of subjects: 260
Study: 12701861

Group type: EXPERIMENTAL
Intervention: Prophylactic intravitreal injection of vancomycin 1 mg and ceftazidime 2.25 mg
Number of subjects: 70

Group type: COMPARATOR
Intervention: Control group (no prophylactic intravitreal antibiotics)
Number of subjects: 70
Study: 11131100

Group type: EXPERIMENTAL
Intervention: Insulin aspart
Number of subjects: 1070
Study: 8930551

Group type: EXPERIMENTAL
Intervention: Pesticide use levels (four levels of pesticide use assigned to municipalities)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pesticide use levels
Number of subjects: 0

Group type: COMPARATOR
Intervention: Level 0 pesticide use (control group)
Number of subjects: 0
Study: 1329475

Group type: EXPERIMENTAL
Intervention: Lisinopril (2.5-10 mg once daily)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Lisinopril (10 mg once daily)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 4054521

Group type: EXPERIMENTAL
Intervention: Ileal infusion of lipid emulsion (50% corn oil, 3% albumen)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Control infusion of albumen and saline
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Ileal infusion of corn oil emulsions
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Intravenous infusion of fat emulsion
Number of subjects: 6

Group type: COMPARATOR
Intervention: Intravenous infusion of isosmotic saline
Number of subjects: 6
Study: 31387615

Group type: EXPERIMENTAL
Intervention: Three-dimensional strapping reduction
Number of subjects: 56

Group type: COMPARATOR
Intervention: Towel clamp reduction
Number of subjects: 56
Study: 27520015

Group type: EXPERIMENTAL
Intervention: Emotional Freedom Techniques (EFT)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: EFT
Number of subjects: 16

Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 16
Study: 29873988

Group type: EXPERIMENTAL
Intervention: Opioid-free anesthesia
Number of subjects: 66

Group type: COMPARATOR
Intervention: Opioid anesthesia
Number of subjects: 66
Study: 25349313

Group type: EXPERIMENTAL
Intervention: Urokinase
Number of subjects: 103

Group type: COMPARATOR
Intervention: Thoracoscopy
Number of subjects: 103
Study: 22727177

Group type: EXPERIMENTAL
Intervention: Low-dose fluocinolone acetonide insert (0.2 μg/d)
Number of subjects: 953

Group type: EXPERIMENTAL
Intervention: High-dose fluocinolone acetonide insert (0.5 μg/d)
Number of subjects: 953

Group type: COMPARATOR
Intervention: Sham injection
Number of subjects: 953
Study: 20214164

Group type: EXPERIMENTAL
Intervention: Intralesional ciprofloxacin (0.2%)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Intralesional sodium chloride hypertonic solution (7%)
Number of subjects: 38
Study: 18056618

Group type: EXPERIMENTAL
Intervention: Dark chocolate
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Milk chocolate
Number of subjects: 0

Group type: COMPARATOR
Intervention: Normal chocolate
Number of subjects: 0

Group type: COMPARATOR
Intervention: No additional chocolate
Number of subjects: 0
Study: 16283906

Group type: EXPERIMENTAL
Intervention: Sodium lauryl sulfate (SLS) at concentrations of 0.025% to 0.075%
Number of subjects: 7

Group type: COMPARATOR
Intervention: Distilled water, acetone, and an empty chamber (controls)
Number of subjects: 7
Study: 11882257

Group type: EXPERIMENTAL
Intervention: Evidence-Based Medicine (EBM)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study: 10530579

Group type: EXPERIMENTAL
Intervention: Cefuroxime axetil (CAE) 30 mg/kg/day in two divided doses for 5 days
Number of subjects: 716

Group type: COMPARATOR
Intervention: Amoxicillin/clavulanate (A/CA-10) 40 mg/kg/day in three divided doses for 10 days
Number of subjects: 716

Group type: COMPARATOR
Intervention: Amoxicillin/clavulanate (A/CA-8) 80 mg/kg/day in three divided doses for 8 days
Number of subjects: 716
Study: 7722188

Group type: EXPERIMENTAL
Intervention: Fermented soy product (112 g tempeh)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Unfermented soy (125 g soybean pieces)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Tempeh diet
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Soy diet (combined fermented and unfermented)
Number of subjects: 17
Study: 1336212

Group type: EXPERIMENTAL
Intervention: Alfentanil (100 mcg/kg i.v. and maintenance of 2-3 mcg/kg/min)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Ventilation with N2O:O2 (1:1)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Naloxone (0.2-0.4 mg) administered after surgery
Number of subjects: 30
Study: 6231418

Group type: COMPARATOR
Intervention: Ampicillin administration
Number of subjects: 5

Group type: COMPARATOR
Intervention: Oxytetracycline (2 X 500 mg/day for 5 days)
Number of subjects: 5

Group type: COMPARATOR
Intervention: Erythromycin for 6 days
Number of subjects: 5

Group type: COMPARATOR
Intervention: Tetracycline and trimethoprim administration
Number of subjects: 5

Group type: COMPARATOR
Intervention: Antimicrobial drugs
Number of subjects: 5

Group type: COMPARATOR
Intervention: Antimicrobial agents
Number of subjects: 5
Study: 31221014

Group type: EXPERIMENTAL
Intervention: CBM instructional approaches (three different approaches)
Number of subjects: 164

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 164
Study: 30157917

Group type: EXPERIMENTAL
Intervention: ARRISA intervention (training staff, flagging records, motivational reminders)
Number of subjects: 10000

Group type: EXPERIMENTAL
Intervention: ARRISA intervention
Number of subjects: 10000

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 10000
Study: 26866874

Group type: EXPERIMENTAL
Intervention: Once-daily transcranial direct current stimulation (tDCS) targeting left frontal and temporo-parietal areas for five days
Number of subjects: 26

Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 26
Study: 25322885

Group type: EXPERIMENTAL
Intervention: Cognitive Processing Therapy (CPT)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Prolonged Exposure (PE)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cognitive-only version of CPT (CPT-C)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both forms of CPT
Number of subjects: 0
Study: 22806212

Group type: EXPERIMENTAL
Intervention: Memantine (16-week treatment)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo (16-week treatment)
Number of subjects: 40
Study: 20699429

Group type: EXPERIMENTAL
Intervention: 8-week proprioceptive training program
Number of subjects: 522

Group type: COMPARATOR
Intervention: usual care
Number of subjects: 522
Study: 17660728

Group type: EXPERIMENTAL
Intervention: Type 1 Diabetes (T1D)
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Newly diagnosed T1D
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Long-standing T1D
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: T1D patients
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: T1D
Number of subjects: 69
Study: 15576392

Group type: EXPERIMENTAL
Intervention: Intramural fibroids group
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group (without fibroids)
Number of subjects: 100
Study: 12200770

Group type: EXPERIMENTAL
Intervention: 30 microg ethinylestradiol/150 microg levonorgestrel (EE/LNG)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: 30 microg ethinylestradiol/75 microg gestodene (EE/GSD)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Both EE/LNG and EE/GSD
Number of subjects: 16